Tipranks Press Release.
Tipranks Press Release.
Vaxcyte (PCVX) has just raised roughly US$1b through concurrent common stock, pre funded warrant and convertible note offerings, following positive Phase 3 data for its VAX 31 pneumococcal vaccine candidate. Recent trading has been strong, with Vaxcyte’s share price at US$66.96 after a 7 day share price return of 17.68% and a year to date share price gain of 44.12%. The 1 year total shareholder return of 64.36% and 5 year total shareholder return of 175.56% point to momentum that has been...
Vaxcyte stays a Strong Buy after VAX-31 phase 3 OPUS-1 success; broader pneumococcal coverage and 2027 catalysts are ahead. Click for more on PCVX.
Biotech stocks took a hit Tuesday, with Vaxcyte, Moderna and Revolution Medicines posting some of the steepest losses.
Key TakeawaysVaxcyte shares fell 10% after the company launched a $1 billion raise, split between $500 million of stock and $500 million of convertible notes, hours after its Phase 3 win. Raising now makes sense – as I noted yesterday – since VAX-31 isn’t due to be filed for approval until the first half of 2028 and Vaxcyte’s spending keeps climbing until then.
Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% to
Vaxcyte (NASDAQ:PCVX) said its investigational 31-valent pneumococcal conjugate vaccine, VAX-31, met all pre-specified primary immunogenicity endpoints in the pivotal Phase III OPUS-1 trial in adults. The randomized, double-blind, active-controlled study enrolled 4,047 U.S. adults, including 3,572
Vaxcyte said earlier on Monday that its experimental pneumonia vaccine, VAX-31, met the main goals of a late-stage study in adults 50 and older.
SAN CARLOS, Calif., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that it has commenced underwritten public offerings of $500 million of its common stock and pre-funded warrants and $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) in separate public offerings registered under the Securities Act of 1933, as amended. All shares of common stock, pre-funded warrants and notes to b
In the OPUS-1 study, Vaxcyte’s VAX-31 matched or beat immune responses from Pfizer’s Prevnar 20 and Merck’s Capvaxive on most strains those vaccines cover.
Here are some of the companies making headlines in midday trading.
Vaxcyte’s vaccine was pitted against standard-of-care jabs and proved non-inferior on nearly all serotypes.
Vaxcyte (NASDAQ:PCVX) shares surged 57% in morning trading on Monday after the biotechnology company said its experimental pneumococcal vaccine VAX-31 generated immune responses comparable to rival vaccines in a late-stage study. The results strengthened expectations that VAX-31 could compete...
Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.
U.S. stocks mixed as Dow falls 250+ points; RXO surges 23% on $5.8B C.H. Robinson deal, while Vaxcyte and PTC post major gains.
Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.
This is the newest page. Registered accounts read further back.